Virtu KCG Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

Virtu KCG Holdings’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$1.28M	Sell	16,014 -15,786	-50%	-$1.01M	0.04%	440
2017 Q1	$1.63M	Buy	31,800 +2,374	+8%	+$110K	0.05%	366
2016 Q4	$1.1M	Buy	29,426 +4,370	+17%	+$183K	0.03%	686
2016 Q3	$1.7M	Buy	25,056 +10,679	+74%	+$753K	0.04%	386
2016 Q2	$798K	Buy	14,377 +1,013	+8%	+$63.8K	0.02%	931
2016 Q1	$839K	Buy	+13,364	New	+$889K	0.02%	713
2015 Q4	–	Sell	-17,737	Closed	-$1.43M	–	3457
2015 Q3	$1.43M	Buy	17,737 +15,490	+689%	+$1.72M	0.02%	627
2015 Q2	$269K	Sell	2,247 -9,762	-81%	-$1.17M	﹤0.01%	2210
2015 Q1	$1.25M	Buy	+12,009	New	+$1.22M	0.03%	611
2014 Q3	–	Sell	-3,892	Closed	-$246K	–	3544
2014 Q2	$246K	Sell	3,892 -2,277	-37%	-$135K	﹤0.01%	2803
2014 Q1	$414K	Buy	+6,169	New	+$478K	0.01%	2166
2013 Q4	–	Sell	-3,154	Closed	-$202K	–	3761
2013 Q3	$202K	Buy	+3,154	New	+$157K	﹤0.01%	3120

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Virtu KCG Holdings's ALNY Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Alnylam Pharmaceuticals (ALNY) stake by 50% in Q2 2017, selling an estimated $1.01M and leaving 16,014 shares worth $1.28M. The position accounts for 0.04% of the portfolio, ranked #440.

Virtu KCG Holdings first reported a position in ALNY in Q3 2013 and has held it in 12 quarters since. The position peaked at $1.7M in Q3 2016. 226 funds tracked by Wall St. Rank hold ALNY as of Q2 2017.

Virtu KCG Holdings held 16,014 shares of Alnylam Pharmaceuticals worth $1.28M as of Q2 2017.
Virtu KCG Holdings sold 15,786 Alnylam Pharmaceuticals shares in Q2 2017, an estimated $1.01M.
Alnylam Pharmaceuticals made up 0.04% of Virtu KCG Holdings's portfolio in Q2 2017, its #440 holding.
Virtu KCG Holdings first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 12 quarters since.
Virtu KCG Holdings's Alnylam Pharmaceuticals position peaked at $1.7M in Q3 2016.
226 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.